Dyslipidemia and lipid management in HIV-infected patients.

Abstract

PURPOSE OF REVIEW:

Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.

RECENT FINDINGS:

Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.

SUMMARY:

Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.

• Authors: Janet Lo
• Journal: Current opinion in endocrinology, diabetes, and obesity (Curr Opin Endocrinol Diabetes Obes) Vol. 18 Issue 2 Pg. 144-7 (Apr 2011) ISSN: 1752-2978 [Electronic] England
• PMID: 21297466 (Publication Type: Journal Article, Review)

Chemical References

• Anti-HIV Agents
• Biomarkers
• Hypolipidemic Agents
• Lipids

Topics

• Anti-HIV Agents (adverse effects, therapeutic use)
• Biomarkers (blood)
• Drug Interactions
• Dyslipidemias (blood, drug therapy, epidemiology, etiology)
• Evidence-Based Medicine
• HIV Infections (complications, drug therapy, epidemiology)
• Humans
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Lipids (blood)
• Risk Assessment
• Treatment Outcome